TDM-105795
TDM-105795 (Topical TRbeta1-Selective Thyromimetic)
First-in-class thyromimetic with Phase 2a data showing modest hair count increases.
How TDM-105795 works — and how well we know it
TRbeta1-selective thyroid hormone receptor agonist. Activates dormant hair follicle stem cells and induces telogen-to-anagen transition via thyroid hormone receptor signaling pathways (Wnt/beta-catenin, Sonic hedgehog, BMP inhibition).
topical
0.02% or 0.0025% once daily (investigational).
Not approved. Phase 2a completed February 2024.
Not available — investigational only.
Evidence distribution across 2 claims
Why the grade is D. One unpublished Phase 2a trial with a modest net effect (+6.3 to +10.3 hairs/cm2 over a high placebo) and no p-values or confidence intervals disclosed, so statistical significance is undemonstrated.
What the studies actually showed
71 males with mild to moderate AGA across 13 U.S. sites
32 healthy males with AGA across 2 U.S. sites
Unknown. The only efficacy measurement was at 16 weeks (4 months). No interim timepoint data has been disclosed. Based on the thyromimetic mechanism (inducing telogen-to-anagen transition), onset could theoretically occur within 2-4 months, but this is speculative.
Unknown. 16 weeks may not represent peak effect; most hair growth trials show continued improvement through 6-12 months. No data beyond 16 weeks exists.
Yes — must continue indefinitely
Unknown. No discontinuation data available. Theoretically, if the compound only induces anagen entry without addressing the underlying androgenic miniaturization process, hair regained may be lost after stopping treatment, but this is speculative.
Side effects, contraindications, and special populations
| Adverse event | Rate | Placebo | Notes |
|---|---|---|---|
| No specific adverse events enumerated | Not disclosed | — | Technoderma reported that both dose strengths were 'well tolerated with no material safety issues identified' across Phase 1 and Phase 2a trials. However, no breakdown of individual adverse events, incidence rates, or AE tables has been published. This lack of granular safety data is a significant gap. |
- None reported (Not disclosed) — No serious adverse events were mentioned in any press release. However, the full safety dataset has not been published in a peer-reviewed journal or at a medical conference.
- Hyperthyroidism or thyrotoxicosis — Theoretical risk of exacerbating thyroid excess via thyromimetic activity, even with minimal systemic exposure. Not formally studied.
- Known hypersensitivity to TDM-105795 or vehicle components — Standard precaution for any topical formulation. Vehicle composition not publicly disclosed.
- Cardiac arrhythmias (atrial fibrillation, supraventricular tachycardia) — Theoretical concern based on thyromimetic class risk. Not formally contraindicated in trials but prudent given unknown long-term systemic exposure.
- Levothyroxine / liothyronine (exogenous thyroid hormones) (Theoretical additive thyromimetic effect if any systemic absorption occurs) — Not studied
- Beta-blockers (Theoretical pharmacodynamic interaction; beta-blockers may mask tachycardia from thyromimetic excess) — Not studied
- Anticoagulants (warfarin) (Thyroid hormones increase catabolism of vitamin K-dependent clotting factors; theoretically relevant if systemic exposure occurs) — Not studied. Likely not clinically relevant given minimal systemic absorption.
Not studied. Pregnancy category not assigned. Thyroid hormones are critical for fetal development, and thyromimetic exposure during pregnancy could theoretically affect fetal thyroid function. Use during pregnancy cannot be recommended.
Not studied. All clinical trials enrolled males only. Efficacy and safety in female pattern hair loss are unknown. A separate clinical development program would be needed.
Not studied. No pediatric data. Use in children cannot be recommended.
Not studied. Phase 2a enrolled males 18-55. Effects in older adults with potential comorbidities (cardiovascular disease, osteoporosis) are unknown.
Not studied.
Not studied. Given TRbeta1 expression in liver and hepatotoxicity signal with other systemic thyromimetics, this population may warrant particular caution.
Every claim, traced back to its source
We took every major claim made about TDM-105795 and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.
2 claims · evidence-by-evidence breakdown
1In VivoWeight: ModerateTDM-105795 is a TRbeta1-selective thyroid hormone receptor agonist for topical hair growthPromising preclinical mechanism but compound-specific data is unpublished.
C3H mice (topical application) and preclinical toxicology in rats and minipigs.
Dose-dependent stimulation of hair growth in mice; induced anagen in telogen-phase follicles.
Preclinical data from company press releases, not peer-reviewed. TRbeta1-selective approach is supported by independent research.
- Technoderma Medicines (2024). Press release
2RCTWeight: ModeratePhase 2a trial showed +24.3 hairs/cm² at 16 weeksModest Phase 2a signal with high placebo response and undisclosed p-values.
Phase 2a RCT, 71 men with AGA, 16 weeks, 13 US sites.
High dose: +24.3 hairs/cm². Placebo: +14.0. Net: +10.3 over placebo.
Modest net effect; high placebo response; p-values not disclosed; unpublished.
- Technoderma Medicines (2024). Phase 2a results press release
What's still missing from the science
- Peer-reviewed publication of any TDM-105795 data
- Disclosed p-values and confidence intervals
- Phase 2b or 3 trial
- Independent research on the compound
Our verdict on TDM-105795
Not in our formulary yet
We don't carry this ingredient. We only formulate around actives where the evidence — and the safety profile — is strong enough to recommend with confidence. As the data matures, we may revisit.
Related treatments
How does TDM-105795 stack up against its closest peers?
First-in-class metabolic approach with strong preclinical rationale, early positive Phase 2a signal, but very limited clinical data and no peer-reviewed publications.
Read the breakdown →Gold standard oral treatment for male AGA with decades of large RCT data proving it slows loss and regrows hair.
Read the breakdown →The most widely studied hair growth agent with 35+ years of RCT evidence in both men and women.
Read the breakdown →